Several brokerages have updated their recommendations and price targets on shares of Thermo Fisher Scientific (NYSE: TMO) in the last few weeks:

  • 8/1/2017 – Thermo Fisher Scientific was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $197.00 price target on the stock. According to Zacks, “Thermo Fisher ended the second quarter on a promising note with both adjusted earnings and revenues beating the Zacks Consensus Estimate. We are particularly upbeat about the company gaining entry into the CDMO market through the agreement to acquire Patheon for $7.2 billion. We are also encouraged by the company’s series of product launches along with major progress in precision medicine initiatives. Thermo Fisher’s acquisition of FEI Company has already started to boost its analytical instruments portfolio. The company also opened Center of Excellence for electron microscopy in Saudi Arabia. This bullish trend has been reflected in the company’s share price performance too. Over the last three months, Thermo Fisher is trading above the broader industry. The raised 2017 guidance is all the more encouraging indicating the fact that this overall bullish trend will continue through the year.”
  • 7/31/2017 – Thermo Fisher Scientific was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Thermo Fisher ended the second quarter on a promising note with both adjusted earnings and revenues beating the Zacks Consensus Estimate. We are particularly upbeat about the company gaining entry into the CDMO market through the agreement to acquire Patheon for $7.2 billion. We are also encouraged by the company’s series of product launches along with major progress in precision medicine initiatives. Thermo Fisher’s acquisition of FEI Company has already started to boost its analytical instruments portfolio. The company also opened Center of Excellence for electron microscopy in Saudi Arabia. This bullish trend has been reflected in the company’s share price performance too. Over the last three months, Thermo Fisher is trading above the broader industry. The raised 2017 guidance is all the more encouraging indicating the fact that this overall bullish trend will continue through the year.”
  • 7/31/2017 – Thermo Fisher Scientific was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/21/2017 – Thermo Fisher Scientific had its “buy” rating reaffirmed by analysts at Bank of America Corporation. They now have a $210.00 price target on the stock, up previously from $200.00.
  • 7/20/2017 – Thermo Fisher Scientific was upgraded by analysts at Cleveland Research from a “neutral” rating to a “buy” rating.
  • 7/17/2017 – Thermo Fisher Scientific had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a $200.00 price target on the stock, up previously from $190.00.
  • 7/13/2017 – Thermo Fisher Scientific had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $200.00 price target on the stock, up previously from $195.00.
  • 7/11/2017 – Thermo Fisher Scientific was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 7/11/2017 – Thermo Fisher Scientific was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $199.00 price target on the stock. According to Zacks, “Over the last three months, Thermo Fisher is trading above the broader Medical – Instruments industry. The company’s last reported first quarter 2017 was quite impressive. The increased 2017 guidance is all the more encouraging indicating the fact that this overall bullish trend will continue through 2017. Moreover we remain encouraged by the company’s series of product launches and acquisitions along with strong growth in emerging markets and better management observed in its customer value proposition. Thermo Fisher’s acquisition of FEI has already started to boost the company’s analytical instruments portfolio. Its recent decision to acquire Pantheon is to expand its biopharma services in Europe. On the flip side, competitive pressure and currency headwinds add woes.”
  • 7/10/2017 – Thermo Fisher Scientific had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a $201.00 price target on the stock, up previously from $182.00.
  • 6/27/2017 – Thermo Fisher Scientific was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.

Thermo Fisher Scientific Inc (NYSE:TMO) opened at 171.74 on Friday. Thermo Fisher Scientific Inc has a one year low of $139.07 and a one year high of $182.87. The stock’s 50 day moving average price is $176.85 and its 200 day moving average price is $165.24. The company has a market capitalization of $67.00 billion, a P/E ratio of 29.92 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The business had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. During the same period in the previous year, the firm posted $2.03 earnings per share. The company’s revenue was up 10.2% on a year-over-year basis. Equities analysts anticipate that Thermo Fisher Scientific Inc will post $9.24 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be issued a $0.15 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.35%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.45%.

In related news, CEO Marc N. Casper sold 20,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $172.79, for a total value of $3,455,800.00. Following the completion of the transaction, the chief executive officer now directly owns 269,279 shares in the company, valued at $46,528,718.41. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction on Monday, June 5th. The shares were sold at an average price of $176.26, for a total value of $440,650.00. Following the completion of the transaction, the chief financial officer now owns 37,790 shares of the company’s stock, valued at $6,660,865.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 27,188 shares of company stock valued at $4,702,223. 0.49% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.